ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,086.37
      0.61%
      US Tech 100
      21,214.46
      1.06%
      Dow Jones
      44,156.73
      0.30%
      Brent Oil
      78.075
      -0.33%
      Bitcoin
      102,855.54
      -0.75%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. GT Biopharma Inc (GTBP) Quote

      GT Biopharma Inc

      GT Biopharma Inc (GTBP)

      GT Biopharma Inc
      2.37
      0.06
      (2.60%)
      Closed January 22 4:00PM
      Delayed by 15 minutes
      2.37
      0.00
      (0.00%)
      After Hours: 7:56PM
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      2.37
      Bid
      2.32
      Ask
      2.37
      Volume
      28,951
      2.202 Day's Range 2.4302
      1.72 52 Week Range 10.6599
      Market Cap
      5.295M
      Previous Close
      2.31
      Open
      2.34
      Last Trade
      5
      @
      2.35
      Last Trade Time
      Financial Volume
      $ 67,017
      VWAP
      2.3149
      Average Volume (3m)
      495,240
      Shares Outstanding
      2,234,328
      Dividend Yield
      -
      PE Ratio
      -0.71
      Earnings Per Share (EPS)
      -3.4
      Revenue
      -
      Net Profit
      -7.6M

      About GT Biopharma Inc

      GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cance... GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its key drug candidates are OXS-2175, targeting the treatment of triple-negative breast cancer; OXS-4235, targets the treatment of multiple myeloma and associated osteolytic lesions; and OXS-1550, targets cancer cells expressing the CD19 receptor and CD22 receptor. Its TriKE and TetraKE platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.gtbiopharma.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      GT Biopharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GTBP. The last closing price for GT Biopharma was $2.31. Over the last year, GT Biopharma shares have traded in a share price range of $ 1.72 to $ 10.6599.

      GT Biopharma currently has 2,234,328 shares outstanding. The market capitalization of GT Biopharma is $5.16 million. GT Biopharma has a price to earnings ratio (PE ratio) of -0.71.

      Ask ADVFN Intelligence (AI)

      GTBP Latest News

      More News

      Form S-1 - General form for registration of securities under the Securities Act of 1933

      December 23 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      November 27 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      November 21 2024
      Edgar (US Regulatory)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      November 14 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      October 21 2024
      Edgar (US Regulatory)

      Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

      October 17 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      September 16 2024
      Edgar (US Regulatory)

      Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

      June 17 2024
      Edgar (US Regulatory)

      Form 3 - Initial statement of beneficial ownership of securities

      June 13 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      June 07 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.09-3.658536585372.462.632.3696582.35057969CS
      4-0.49-17.13286713292.863.21.99073057032.49038382CS
      12-0.83-25.93753.24.11.724952402.75908972CS
      26-0.32-11.89591078072.694.11.722244182.74646827CS
      52-4.68-66.38297872347.0510.65991.724689696.06774512CS
      156-73.53-96.877470355775.9112.21.7228294817.77226221CS
      260-162.63-98.5636363636165591.9931.7231604799.74925971CS

      GTBP - Frequently Asked Questions (FAQ)

      What is the current GT Biopharma share price?
      The current share price of GT Biopharma is $ 2.37
      How many GT Biopharma shares are in issue?
      GT Biopharma has 2,234,328 shares in issue
      What is the market cap of GT Biopharma?
      The market capitalisation of GT Biopharma is USD 5.16M
      What is the 1 year trading range for GT Biopharma share price?
      GT Biopharma has traded in the range of $ 1.72 to $ 10.6599 during the past year
      What is the PE ratio of GT Biopharma?
      The price to earnings ratio of GT Biopharma is -0.71
      What is the reporting currency for GT Biopharma?
      GT Biopharma reports financial results in USD
      What is the latest annual profit for GT Biopharma?
      The latest annual profit of GT Biopharma is USD -7.6M
      What is the registered address of GT Biopharma?
      The registered address for GT Biopharma is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
      What is the GT Biopharma website address?
      The website address for GT Biopharma is www.gtbiopharma.com
      Which industry sector does GT Biopharma operate in?
      GT Biopharma operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      BLBXBlackBoxStocks Inc
      $ 5.53
      (227.22%)
      		229.08M
      ASSTAsset Entities Inc
      $ 1.36
      (51.11%)
      		121.68M
      STAIScanTech AI Systems Inc
      $ 2.12
      (44.22%)
      		51.68M
      JYDJayud Global Logistics Ltd
      $ 3.53
      (42.91%)
      		1.27M
      NTRBNutriband Inc
      $ 7.39
      (41.84%)
      		3.88M
      STFSStar Fashion Culture Holdings Ltd
      $ 2.62
      (-80.61%)
      		30.25M
      HEPAHepion Pharmaceuticals Inc
      $ 0.135
      (-58.05%)
      		39.78M
      STBXStarBox Group Holdings Ltd
      $ 0.6201
      (-36.50%)
      		1.63M
      WHLRLWheeler Real Estate Investment Trust Inc
      $ 93.51
      (-35.73%)
      		1
      JUNSJupiter Neurosciences Inc
      $ 3.61
      (-33.39%)
      		6.87M
      IPAImmunoPrecise Antibodies Ltd
      $ 0.6446
      (30.75%)
      		296.43M
      TNXPTonix Pharmaceuticals Holding Corporation
      $ 0.3191
      (33.57%)
      		229.11M
      BLBXBlackBoxStocks Inc
      $ 5.53
      (227.22%)
      		229.08M
      NVDANVIDIA Corporation
      $ 147.07
      (4.43%)
      		216.62M
      RGTIRigetti Computing Inc
      $ 13.89
      (-0.64%)
      		154.54M

      GTBP Discussion

      View Posts
      BurgerKing82 BurgerKing82 4 weeks ago
      Hmmm... interesting
      👍️0
      glenn1919 glenn1919 1 month ago
      GTBP................................................p/m
      👍️0
      philaya philaya 8 months ago
      buy the dip....
      low low.
      👍️0
      philaya philaya 8 months ago
      Got in...
      Happy losing day.
      👍️0
      TheFinalCD TheFinalCD 8 months ago
      https://x.com/READY_2_PROFIT/status/1792903871624327515
      👍️0
      tw0122 tw0122 8 months ago
      Didn’t participate in earlier todays squeeze but 100,000 shares available only. Nice continuation
      👍️0
      TheFinalCD TheFinalCD 8 months ago
      GTBP https://x.com/GBearTrading/status/1792907456361713969
      👍️0
      Awl416 Awl416 8 months ago
      LOL
      👍️0
      Monksdream Monksdream 8 months ago
      Early Barchart 100
      https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
      👍️0
      Awl416 Awl416 8 months ago
      Wils
      👍️0
      Invest-in-America Invest-in-America 8 months ago
      Regarding @RONN, no tip was given to me about it at all --- indeed, the FIRST time I heard about was from YOUR post to me over here.
      👍️0
      Invest-in-America Invest-in-America 8 months ago
      GTBP: Nope; I simply follow the daily posts of iHub's "tw0122", who was the first to post in here on this one.
      👍️0
      reena969 reena969 8 months ago
      I've been trying to find you Did you take the tip that was given to you?

      https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174447373
      👍️0
      govprs govprs 8 months ago
      Joker!!! Looks like it’s halted again
      👍️0
      bwrbad bwrbad 8 months ago
      no future - be at 50c
      👍️0
      Invest-in-America Invest-in-America 8 months ago
      GTBP: Halted!!
      👍️0
      govprs govprs 8 months ago
      I’m still holding what’s all the excitement about
      👍️0
      Invest-in-America Invest-in-America 8 months ago
      GTBP: Still holding --- 4-bagger later today??????
      👍️0
      tw0122 tw0122 8 months ago
      Moon man summary 90% institutional ownership by Girozentrale on 1m float leaves 100,000 shares for retail to pump. June catalyst
      👍️0
      Otis T Otis T 10 months ago
      One year price target of $153. Published post split, article available on NASDAQ.com.
      👍️0
      Muhbruh Muhbruh 10 months ago
      https://twitter.com/StocksGambino/status/1767630737845391730
      👍️0
      Renee Renee 12 months ago
      GTBP: effective Feb. 5,2024 a one for 30 reverse split:

      https://hedgefollow.com/upcoming-stock-splits.php
      👍️0
      Plummy Potter Plummy Potter 1 year ago
      Anyone have access to the latest HCW or EF Hutton research reports?
      👍️0
      Triple nickle Triple nickle 1 year ago
      Nice grab
      👍️0
      limer814 limer814 2 years ago
      Sure is ,and this sudden burst in volume is telling, added today
      👍️0
      Triple nickle Triple nickle 2 years ago
      This is the bottom folks
      👍️0
      Triple nickle Triple nickle 2 years ago
      Weeee
      👍️0
      Triple nickle Triple nickle 2 years ago
      A little bit
      👍️0
      limer814 limer814 2 years ago
      Action!!
      👍️0
      limer814 limer814 2 years ago
      The big three 0
      👍️ 1
      SittingPretty SittingPretty 2 years ago
      saw that too. these bios are beat to hell... should eventually get back some public trust
      👍️0
      limer814 limer814 2 years ago
      Nice buys coming in
      👍️0
      SittingPretty SittingPretty 2 years ago
      Nice! Should be hearing something from these guys... hopefully soon.
      👍️0
      limer814 limer814 2 years ago
      Nice buys coming in
      👍️0
      SittingPretty SittingPretty 2 years ago
      Regret not waiting... what a crap show lol
      👍️0
      SittingPretty SittingPretty 2 years ago
      Have to admit, grateful to accumulate at these prices. $GTBP is far along in its process with FDA and others obviously know it. That $175k Form 4 purchase filing last week was telling!
      https://www.otcmarkets.com/filing/html?id=16743896&guid=2aT-knKRHtwfJth
      👍️0
      SittingPretty SittingPretty 2 years ago
      Good morning $GTBP
      👍️0
      diskman diskman 2 years ago
      Very interesting
      👍️ 1
      SittingPretty SittingPretty 2 years ago
      Good Morning Did you see this? Think we're getting close to some good news. Check it out:

      Charles Casamento - Executive Director & Principal - The Sage Group purchased $175k worth of $GTBP @ .35 on 6/16/2023. Filed Form 4 on 06/21/2023
      https://www.otcmarkets.com/filing/html?id=16743896&guid=-HT-kenyprHRB3h

      Charles J. Casamento is currently Executive Director and Principal of The Sage Group, a healthcare advisory group specializing in mergers, acquisitions, and partnerships between biotechnology companies and pharmaceutical companies, since 2007.
      https://www.linkedin.com/in/charles-casamento-b1a9173
      👍️0
      SittingPretty SittingPretty 2 years ago
      Wow, L2 going crazy. Hopefully this is the flush out and then ready for higher ground!
      👍️0
      SittingPretty SittingPretty 2 years ago
      Absolutely! Grabbed a bunch a few mins ago. Wow! What a pullback.
      👍️0
      Triple nickle Triple nickle 2 years ago
      Another day of adding here
      👍️0
      SittingPretty SittingPretty 2 years ago
      Nice! I'm right here with ya loading Good day for it!
      👍️0
      limer814 limer814 2 years ago
      Loaded some more today
      👍️0
      SittingPretty SittingPretty 2 years ago
      Great loading day!
      👍️0
      WARHAMMER WARHAMMER 2 years ago
      Lol
      👍️0
      Triple nickle Triple nickle 2 years ago
      Prosperity favors the bold
      Can’t never could and won’t never will
      👍️ 1
      WARHAMMER WARHAMMER 2 years ago
      Sounds Dam good to me :)
      👍️0
      WARHAMMER WARHAMMER 2 years ago
      ??!!
      👍️0
      Triple nickle Triple nickle 2 years ago
      First target 1.12 second one 4.77
      👍️0

      Your Recent History

      NASDAQ
      GTBP
      GT Biopharma
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads